Overall Risk Patients Analysis (n = 372) | |||
---|---|---|---|
Age (yr) | Median (range) | 68 (43–76) | |
PSA | Median (range) | 7.8 (2.78–90.5) | |
PSAD | Median (range) | 0.3 (0.06–5.36) | |
Risk Stratification | Low (%) | 46 (12) | |
Intermediate | Favorable (%) | 96 (26) | |
Unfavorable (%) | 80 (22) | ||
High (%) | 127 (34) | ||
Very high (%) | 23 (6) | ||
GGa | 1 (%) | 41 (11) | |
2 (%) | 141 (38) | ||
3 (%) | 90 (24) | ||
4 (%) | 36 (10) | ||
5 (%) | 64 (17) | ||
LVI | Positive (%) | 37 (10) | |
EPE | Positive (%) | 105 (28) | |
SM | Positive (%) | 111 (30) | |
SVI | Positive (%) | 30 (8) | |
IDCP | Positive (%) | 66 (18) | |
pT | 2 (%) | 265 (71) | |
3a (%) | 77 (21) | ||
3b (%) | 30 (8) | ||
Follow-up Duration (mo) | Median (range) | 18 (0–74) |